Active substance
Lorazepam
- SFDA 2
- US FDA 74
- Health Canada 17
- US price lines 6
- NHS prices 7
- WHO EML 2
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ATIVAN TABLETS 1 MG | 1 mg | Tablet · Oral use | 20 Blister | SAR 14.90 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| ATIVAN TABLETS 2 MG | 2 mg | Tablet · Oral use | 20 Blister | SAR 19.80 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ATIVAN | 0.5MG; 1MG; 2MG | tablet · oral | BAUSCH | Prescription | 30 Sep 1977 |
| ATIVAN | 2MG/ML; 4MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 25 Jul 1980 |
| LORAZEPAM | 0.5MG | tablet · oral | Prescription | 21 Apr 1987 | |
| LORAZEPAM | 2MG; 0.5MG; 1MG | tablet · oral | SANDOZ | Prescription | 21 Apr 1987 |
| LORAZEPAM | 1MG | tablet · oral | SANDOZ | Prescription | 21 Apr 1987 |
| LORAZEPAM INTENSOL | 2MG/ML | concentrate · oral | HIKMA PHARMS | Prescription | 28 Jun 1991 |
| LORAZEPAM | 0.5MG | tablet · oral | WATSON LABS | Prescription | 31 Oct 1991 |
| LORAZEPAM | 1MG | tablet · oral | WATSON LABS | Prescription | 31 Oct 1991 |
| LORAZEPAM | 2MG | tablet · oral | WATSON LABS | Prescription | 31 Oct 1991 |
| LORAZEPAM | 2MG/ML; 4MG/ML | injectable · injection | HOSPIRA | Prescription | 12 Apr 1994 |
| LORAZEPAM | 2MG/ML | injectable · injection | RISING | Prescription | 23 Jul 1998 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | SUN PHARM INDS LTD | Prescription | 29 Aug 2001 |
| LORAZEPAM | 2MG/ML | injectable · injection | INTL MEDICATION SYS | Prescription | 15 Nov 2004 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | OXFORD PHARMS | Prescription | 10 May 2006 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | ANI PHARMS | Prescription | 13 Dec 2006 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | LEADING | Prescription | 30 Jul 2007 |
| LORAZEPAM | 2MG/ML | concentrate · oral | AMNEAL PHARMS | Prescription | 23 Dec 2009 |
| LORAZEPAM | 2MG/ML | concentrate · oral | PHARM ASSOC | Prescription | 15 Jun 2010 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | AUROBINDO PHARMA | Prescription | 22 Dec 2017 |
| LOREEV XR | 1MG; 2MG; 3MG; 1.5MG | capsule, extended release · oral | ALMATICA | Prescription | 27 Aug 2021 |
| LORAZEPAM | 2MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 18 Nov 2024 |
| LORAZEPAM | 0.5MG; 1MG; 2MG | tablet · oral | GRAVITI PHARMS | Prescription | 24 Jul 2025 |
| LORAZEPAM | 0.5MG | tablet · oral | MUTUAL PHARM | Discontinued | 10 Dec 1985 |
| LORAZEPAM | 1MG | tablet · oral | MUTUAL PHARM | Discontinued | 10 Dec 1985 |
| LORAZEPAM | 2MG | tablet · oral | MUTUAL PHARM | Discontinued | 10 Dec 1985 |
49 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LORAZEPAM | 00655740 | 0.5 MG | TABLET · ORAL | APOTEX INC |
| APO-LORAZEPAM | 00655759 | 1 MG | TABLET · ORAL | APOTEX INC |
| APO-LORAZEPAM | 00655767 | 2 MG | TABLET · ORAL | APOTEX INC |
| LORAZEPAM INJECTION USP | 02243278 | 4 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| LORAZEPAM INJECTION, USP | 02550962 | 4 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| LORAZEPAM SUBLINGUAL | 02410745 | 0.5 MG | TABLET · SUBLINGUAL | AA PHARMA INC |
| LORAZEPAM SUBLINGUAL | 02410753 | 1 MG | TABLET · SUBLINGUAL | AA PHARMA INC |
| LORAZEPAM SUBLINGUAL | 02410761 | 2 MG | TABLET · SUBLINGUAL | AA PHARMA INC |
| PMS-LORAZEPAM | 00728187 | 0.5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-LORAZEPAM | 00728195 | 1 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-LORAZEPAM | 00728209 | 2 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PRO-LORAZEPAM | 00655643 | 0.5 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-LORAZEPAM | 00655651 | 1 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRO-LORAZEPAM | 00655678 | 2 MG | TABLET · ORAL | PRO DOC LIMITEE |
| TEVA-LORAZEPAM | 00637742 | 1 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LORAZEPAM | 00637750 | 2 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LORAZEPAM | 00711101 | 0.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LORAZEPAM 0.5 MG TABLET | $0.03443 | per EA | 23 Sep 2026 |
| US NADAC | LORAZEPAM 1 MG TABLET | $0.03671 | per EA | 23 Sep 2026 |
| US NADAC | LORAZEPAM 2 MG TABLET | $0.07314 | per EA | 23 Sep 2026 |
| US NADAC | LORAZEPAM 2 MG/ML ORAL CONCENT | $0.68632 | per ML | 23 Sep 2026 |
| US NADAC | LORAZEPAM 2 MG/ML VIAL | $2.17153 | per ML | 23 Sep 2026 |
| US NADAC | LORAZEPAM INTENSOL 2 MG/ML | $0.68632 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Lorazepam 1mg orodispersible tablets | £37.58 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 1mg tablets | £2.05 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 1mg/ml oral solution sugar free | £270.44 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 2.5mg tablets | £2.22 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 250microgram tablets | £55.20 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 4mg/1ml solution for injection ampoules | £199.00 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Lorazepam 500microgram tablets | £1.54 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.1. Antiseizure medicines · core
Status epilepticus
Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule - 24.3. Medicines for anxiety disorders · core
Therapeutic equivalent to diazepam for Anxiety
Safety signals and safety-related labeling changes
- EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - US FDA 13 Jan 2023 ATIVAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jan 2023 ATIVAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jan 2023 LOREEV XR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 11 Dec 2014 Lorazepam: reduction of recommended maximum daily dose
Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe, disabling insomnia
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.